Surgalign Introduces Fortilink® Portfolio With TiPlus™ Technology Products, Expanding Its Addressable Market for Interbody Fusion Procedures

Expanded Fortilink interbody product line, now including titanium and 3D printed polymer options.

DEERFIELD, Illinois, Sept. 26, 2022 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on advancing standards of care by advancing digital health, today announced the expansion of its Fortilink product portfolio with the launch of a new line and commercial launch Or an interbody fusion device with TiPlus technology.

The new implants include the Fortilink-A with TiPlus technology for anterior lumbar interbody fusion (ALIF) procedures; the Fortilink-TC and -TS with TiPlus technology for posterior lumbar interbody fusion (PLIF/TLIF) ) surgery; and the Fortilink-C with TiPlus Technology for Anterior Cervical Discectomy and Fusion (ACDF) surgery.

The new line of 3D printed titanium (Ti) alloy interbody cages is fully porous and designed to take advantage of 3D printed manufacturing without compromising clinical requirements. Featuring interconnect architecture and acid-etched nanosurfaces, Fortilink-A, -TC, -TS, and -C with TiPlus technology are available in a variety of footprint and hyperprotrusion products designed for primary stability and bone ingrowth.1

The Fortilink Interbody Fusion (IBF) line of implants with TiPlus technology was designed with direct input from leading medical practitioners and was designed to incorporate features that surgeons seek in titanium interbody fusion devices. The system features streamlined instrumentation and multiple implant sizes, allowing surgeons to implant their preferred choice for patients.

“TiPlus is a great new product that greatly supports the interbody solutions I can offer my patients based on their specific clinical needs,” Dr. Dr. said. Jon White, an orthopedic spine surgeon at the Hogg Orthopaedic Institute in Irvine, Calif. “The acid-etched surface and optimized pore size allow for bone ingrowth and ingrowth, providing confidence in achieving good patient outcomes.”

PhD. Aaron Creek, a spine surgeon at the Florida Neck Research Institute in Destin, added: “In addition to the existing TETRAfuse 3D printed polymer options, the expansion of the Fortilink system includes a 3D printed titanium implant, a unique and Efficient solution. Utilizing the well-designed Fortilink instrument—but offering implants in two different biomaterials—allows me to better tailor treatments to my patients.”

To learn more about the Fortilink product portfolio sold by Surgalign, please visit:

About Surgalign Holdings, Inc.
Surgalign Holdings, Inc. is a global medical technology company committed to transforming the entire surgical field through digital health. The company advances the standard of care with a unique approach and resources focused on building technology where physicians and other healthcare providers will seek what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign sells its products in the US and approximately 50 countries around the world through an expanding network of top independent distributors. Surgalign is headquartered in Deerfield, Illinois, with business, innovation and design centers in San Diego, California; Warsaw and Poznan, Poland; and Wormlingen, Germany. Visit to learn more and connect on LinkedIn and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements based on management’s current expectations, estimates and projections about our products, company and industry, management’s beliefs and certain assumptions made by management. Words such as “anticipate,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” and other variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including those described in our public filings with the Securities and Exchange Commission (SEC). Our actual results may differ materially from the expected results reflected in these forward-looking statements. Copies of the company’s filings with the SEC may be obtained by contacting the company or the SEC or by visiting Surgalign’s website: or the SEC’s website

1 Data archived by Baat Medical.

Source link